0
Following a pre-signed agreement in October 2018, Boehringer Ingelheim and Dopharma are announcing today the effective acquisition of the Saint-Herblon (France, Loire-Atlantique) production site and the Coophavet brand by Dopharma. This independent and family-owned Dutch company develops, produces and distributes veterinary products 100 per cent dedicated to livestock.
This sale is part of Boehringer Ingelheim Animal Health’s strategic refocusing on advanced and preventive animal healthcare; Saint-Herblon mainly producing generics and antibiotics for livestock, under the Coophavet brand.
For Dopharma, a growing player on the market, already distributing in more than 50 countries, this acquisition represents a significant asset in addition to its European-based production sites.
Boehringer Ingelheim had taken the effort to identify a strong buyer in order to offer a sustainable future for the site and its employees. By establishing its presence in France, and thanks to its complementary portfolio, Dopharma’s ambition is indeed to develop the site and Coophavet’s activity as well as its international presence. Moreover, Boehringer Ingelheim and Dopharma will continue to collaborate in the coming years to manufacture some specialised products.
April 1, 2019 – Boehringer Ingelheim
